Science & Technology
Use of Apatinib-nanosponge conjugate to reduce post-radiation induced oral cavity and salivary fibrosis.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41DE034312-01A1
Award Ceiling
$299K
Award Floor
$299K
Close Date
Aug 19, 2026
157 days leftTotal Funding
$299K
Expected Awards
1
Posted Date
Aug 20, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41DE034312-01A1
Description
STTR Phase Phase I award: "Use of Apatinib-nanosponge conjugate to reduce post-radiation induced oral cavity and salivary fibrosis." awarded to DELTAMED LLC in Kansas City, Missouri. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $298,942. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.